CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Cholesterol-Lowering Agents The Current State of Left Main Percutaneous Coronary Intervention Know Diabetes by Heart: A Partnership to Improve Cardiovascular Outcomes in Type 2 Diabetes Mellitus Impact of different final optimization techniques on long-term clinical outcomes of left main cross-over stenting Comparative Accuracy of Focused Cardiac Ultrasonography and Clinical Examination for Left Ventricular Dysfunction and Valvular Heart Disease: A Systematic Review and Meta-analysis Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications Chronic Kidney Disease and Coronary Artery Disease Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Original Research2021 Jan 10;S1547-5271(21)00009-6.

JOURNAL:Heart Rhythm. Article Link

Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden

S Tankut, I Goldenberg, V Kutyifa et al. Keywords: cardiac resynchronization therapy; heart failure; left bundle branch block; ventricular fibrillation; ventricular tachycardia arrhythmia.

ABSTRACT


BACKGROUND - Cardiac resynchronization therapy-defibrillator (CRT-D) may reduce the incidence of first ventricular tachyarrhythmia (VTA) in patients with heart failure (HF) and left bundle-branch-block (LBBB).

 

OBJECTIVE - To assess the effect of CRT-D on VTA burden in LBBB patients.

 

METHODS - We included 1281 patients with LBBB from MADIT-CRT. VTA was defined as any treated or monitored sustained ventricular tachycardia (VT180 bpm) or ventricular fibrillation (VF). Life-threatening VTA was defined as VT200 bpm or VF. VTA recurrence was assessed using the Andersen-Gill model.

 

RESULTS - During a mean follow-up of 2.5 years, 964 VTA episodes occurred in 264 (21%) patients. The VTA rate per 100 person-years was significantly lower in the CRT-D group when compared with the ICD group (20 vs. 34; respectively; p<0.01). Multivariate analysis demonstrated that CRT-D treatment was associated with a 32% risk reduction for VTA recurrence (HR=0.68; 95%CI 0.57-0.82; p<0.001), 57% risk reduction for recurrent life-threatening VTA, 54% risk reduction for recurrent appropriate ICD-shocks, and a 25% risk reduction for the combined endpoint of VTA and death. The effect of CRT on VTA burden was consistent among all tested subgroups, but was more pronounced among NYHA class I patients. Landmark analysis showed that at 2 years, the cumulative probability of death subsequent to year one was highest (16%) among patients who had 2 VTA events during their first year.

 

CONCLUSION - In patients with LBBB and HF, early intervention with CRT-D reduces mortality, VTA burden, and frequency of multiple appropriate ICD shocks. VTA burden is a powerful predictor of subsequent mortality.